Market Place
Sourcing Support
Imvax to Present Safety Data on IGV-001 at 2024 SNO Annual Meeting
11 Nov 2024 //
BUSINESSWIRE
Imvax Completes IGV-001 Phase 2b Enrollment, Funding Round
21 May 2024 //
BUSINESSWIRE
Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its IGV-001
20 Nov 2023 //
BUSINESSWIRE
Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting
10 Nov 2023 //
BUSINESSWIRE
Imvax Provides Corporate Update
06 Sep 2023 //
BUSINESSWIRE
Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action
17 Apr 2023 //
BUSINESSWIRE
Imvax Announces First Patient Dosed in Ph 2b Trial of IGV-001 for Glioblastoma
27 Mar 2023 //
BUSINESSWIRE
Imvax to Present Data on Tumor-Derived Immunotherapy Platform at SITC Meeting
06 Oct 2022 //
BUSINESSWIRE
Imvax Presents Data on Whole-Tumor Derived Immunotherapeutic Platform
29 Sep 2022 //
BUSINESSWIRE
Imvax Presents New Data on Tumor-Derived Immunotherapies in Solid Tumors at AACR
08 Apr 2022 //
BUSINESSWIRE
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR
09 Mar 2022 //
BUSINESSWIRE
Imvax Presents Data Showing Mechanisms for Broad Immune Activation by IGV-001
09 Nov 2021 //
BUSINESSWIRE
Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC
21 Oct 2021 //
BUSINESSWIRE
Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001 for Patients
26 Jan 2021 //
PRNEWSWIRE
Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001
26 Jan 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.